GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NetScientific PLC (LSE:NSCI) » Definitions » COGS-to-Revenue

NetScientific (LSE:NSCI) COGS-to-Revenue : 0.07 (As of Jun. 2023)


View and export this data going back to 2013. Start your Free Trial

What is NetScientific COGS-to-Revenue?

NetScientific's Cost of Goods Sold for the six months ended in Jun. 2023 was £0.05 Mil. Its Revenue for the six months ended in Jun. 2023 was £0.77 Mil.

NetScientific's COGS to Revenue for the six months ended in Jun. 2023 was 0.07.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. NetScientific's Gross Margin % for the six months ended in Jun. 2023 was 93.12%.


NetScientific COGS-to-Revenue Historical Data

The historical data trend for NetScientific's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NetScientific COGS-to-Revenue Chart

NetScientific Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.32 0.16 0.12 0.11 0.22

NetScientific Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.12 0.08 0.31 0.07

NetScientific COGS-to-Revenue Calculation

NetScientific's COGS to Revenue for the fiscal year that ended in Dec. 2022 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.222 / 1.004
=0.22

NetScientific's COGS to Revenue for the quarter that ended in Jun. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.053 / 0.77
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NetScientific  (LSE:NSCI) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

NetScientific's Gross Margin % for the six months ended in Jun. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0.053 / 0.77
=93.12 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


NetScientific COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of NetScientific's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


NetScientific (LSE:NSCI) Business Description

Traded in Other Exchanges
N/A
Address
20 Saint Andrew Street, Holborn Circus, London, GBR, EC4A 3AG
NetScientific PLC is a transatlantic healthcare technology company. The group is focused on sourcing, funding and commercializing technologies and companies that have the potential to treat chronic disease and significantly improve the health and well-being of people. Its portfolio consists of WANDA Health, an analytics company that uses machine learning to derive a personalized risk score for Congestive Heart Failure patients, Glucosense a provider of a non-invasive glucose monitoring wearable device, Vortex Biosciences which is engaged in circulating tumor cell identification, selection and analysis for disease monitoring and personalized therapeutic prescribing, and Glycotest which provides non-invasive blood tests for liver cancers and fibrosis-cirrhosis.

NetScientific (LSE:NSCI) Headlines

No Headlines